Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
A key health ministry reimbursement panel on April 11 gave the nod to NHI prices for a batch of new drugs for their listing on April 18, including big names like Dupixent (dupilumab), Tecentriq (atezolizumab), and Lynparza (olaparib). Meanwhile, Parmodia…
To read the full story
Related Article
- Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018
- In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
November 20, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
REGULATORY
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
- LDP Study Group’s Honebuto Proposal Urges “Freeze” on On-Patent Drug Price Cuts
May 20, 2026
- PMDA Flags Iron Products, ST Combination Drug in Risk Review
May 20, 2026
- MHLW Orders Detailed Report on Tavneos Efficacy Concerns
May 20, 2026
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…